Features Partner Sites Information LinkXpress
Sign In
Demo Company

Automated Sample and Liquid Handling Platforms Suited for All Lab Sizes

By BiotechDaily International staff writers
Posted on 08 Jul 2014
Print article
Tecan Fluent laboratory automation solution
Automated Sample and Liquid Handling Platform (Photo courtesy of TECAN GROUP LTD.)
Biotech and other life scientists who work with cell-based assays now have available a new line of advanced automated sample and liquid handling platforms.

Tecan (Männedorf, Switzerland) has introduced the Fluent laboratory automation solution, the latest addition to its laboratory automation portfolio.

The Fluent system is available in three sizes—offering deck capacities from 30 to 72 microplates—to suit the throughput requirements of almost any laboratory. The instrument boasts a built-in touchscreen interface that guides users through every task, making even the most sophisticated cell-based assays easy to run. Fluent’s three, task-specific robotic arms work in parallel for faster processing, and offer automated lid handling to maintain sterility and minimize evaporation.

The Fluent platform was designed for integration with a variety of cell biology devices. This allows the user to control every step of the workflow, including storage, transfer, manipulation, and measurement of cellular samples on a single instrument.

The Tecan HydroSpeed plate washer features extra-gentle wash settings that can be adjusted to suit specific cells, microplates, and applications, ensuring reproducible results even with weakly adherent cells.

“Today’s research landscape looks different from yesterday’s, with customers wanting systems that are faster, more versatile, and more cost efficient,” said Dr. Stefan Traeger, head of life sciences business at Tecan. “The Fluent laboratory automation solution has initially been developed to address the needs of cell biology laboratories as they move towards greater miniaturization and higher throughput assays, and our test sites and assay partners have been impressed by its speed and capabilities for automating even complex cell-based assays.”

Related Links:


Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
  • Free digital version edition of Bio Research International sent by email on regular basis
  • Free print version of Bio Research International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Bio Research International in digital format
  • Free Bio Research International Newsletter sent every 2 weeks containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register




view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.